{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-178954","form_type":"8-K","ticker":"VRCA","cik":"0001660334","company_name":"Verrica Pharmaceuticals Inc.","filed_at":"2025-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.584909+00:00","generated_at":"2026-05-17T14:39:28.692969+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Verrica Q2 net income $0.2M; YCANTH units +32.8% QoQ; Nasdaq compliance regained","bullets":["Q2 product revenue $4.5M; license & collaboration revenue $8.2M (incl. $8.0M Torii milestone). Net income $0.2M ($0.02 GAAP EPS) vs net loss $17.2M YoY.","YCANTH dispensed applicator units 13,434, sequential growth of 32.8% over Q1'25. Revenue net $4.5M up 32.5% sequentially.","Regained Nasdaq bid price compliance after 1-for-10 reverse stock split on July 24, 2025.","Torii accelerated $8M milestone payment received July 2025; additional $10M milestone upon Japanese YCANTH approval expected by end of 2025.","Completed End-of-Phase 2 meeting with FDA for VP-315 (basal cell carcinoma); preparing Phase 3 program and exploring non-dilutive funding."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-178954","json":"https://secwatch.observer/filing/0001193125-25-178954.json","markdown":"https://secwatch.observer/filing/0001193125-25-178954.md","text":"https://secwatch.observer/filing/0001193125-25-178954.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1660334/000119312525178954/0001193125-25-178954-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1660334/000119312525178954/d409147d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:39:28.692969+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}